To hear about similar clinical trials, please enter your email below
Trial Title:
Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting
NCT ID:
NCT05826756
Condition:
Lung Cancer Patients
Caregivers
Conditions: Official terms:
Lung Neoplasms
Conditions: Keywords:
Lung cancer
Patient
Caregiver
Smoker
Non-smoker
Tobacco use
Tobacco exposure
Biomarker
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Quality of life
Treatment
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
There are no interventions in this study. All participants complete online surveys.
Description:
There are no interventions in this study. All participants complete online surveys.
Arm group label:
Caregivers
Arm group label:
Patients
Other name:
Other
Summary:
LUNGevity Foundation, a non-profit lung cancer organization, wants to learn about living
with lung cancer from the point of view of people with lung cancer and their family and
friends who provide care. To do this, we have an online study designed to better
understand how treatments people living with lung cancer receive impact their quality of
life. Participants will complete surveys once a month for 12 months.
What does participation involve?
1. Emailing the study team to learn more and get access to the study website.
2. Once a month for 12 months you will receive a survey by email.
3. Complete these surveys on a smartphone, tablet, or computer at your convenience and
receive an e-gift card for your time.
Detailed description:
PEER is an international study, that is Institutional Review Board (IRB) approved and
General Data Protection Regulation (GDPR) compliant.
The study objective is to collect longitudinal data to facilitate a rigorous
understanding of the diagnostic and treatment experiences of people diagnosed with lung
cancer and to identify determinants of treatment heterogeneity. Study data will be used
to understand the diagnostic and treatment pathways, explore patient-experience data in
different domains (financial impact/quality of life/symptoms) and test the hypothesis
that different classes of therapies (chemotherapy/ immunotherapy/ targeted therapy/
surgery/ radiation) impact patient experience (eg., physical function).
Study participants will consent and register for the study and complete an initial
baseline survey. They will then be followed for 12 months and receive a monthly survey
(11 surveys in total) via email. The development of the surveys was guided by input from
patients, clinicians, FDA experts, and incorporates questions from existing
patient-reported outcomes (PRO) measures.
Summarized study results will also be posted on LUNGevity's website. External researchers
will be able to apply to have limited access to de-identified data.
Criteria for eligibility:
Study pop:
People who have been diagnosed with lung cancer and family and friends who care for
someone with a lung cancer diagnosis. PEER is an international study, so participants can
live anywhere as long as they meet the inclusion criteria.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Adults with self-reported lung cancer diagnosis or caregiver of someone with a
self-reported lung cancer diagnosis (patient has to be alive)
- Ability to read and answer questions in English
- Access and ability to use a computer or other internet-connected device
Exclusion Criteria:
- Younger than 18
- Healthcare providers and healthcare professionals who provide care to lung cancer
patients except for those who are themselves a patient or a caregiver to a loved
one.
- Not able to provide informed consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
LUNGevity Foundation
Address:
City:
Bethesda
Zip:
20814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Bellinda King-Kallimanis, PhD
Email:
ProjectPEER@lungevity.org
Start date:
August 15, 2020
Completion date:
December 2025
Lead sponsor:
Agency:
LUNGevity Foundation
Agency class:
Other
Collaborator:
Agency:
Amgen
Agency class:
Industry
Collaborator:
Agency:
AstraZeneca
Agency class:
Industry
Collaborator:
Agency:
Blueprint Medicines Corporation
Agency class:
Industry
Collaborator:
Agency:
Boehringer Ingelheim
Agency class:
Industry
Collaborator:
Agency:
Bristol-Myers Squibb
Agency class:
Industry
Collaborator:
Agency:
Eli Lilly and Company
Agency class:
Industry
Collaborator:
Agency:
G1 Therapeutics, Inc.
Agency class:
Industry
Collaborator:
Agency:
Genentech, Inc.
Agency class:
Industry
Collaborator:
Agency:
Janssen, LP
Agency class:
Industry
Collaborator:
Agency:
Jazz Pharmaceuticals
Agency class:
Industry
Collaborator:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Collaborator:
Agency:
Novartis
Agency class:
Industry
Collaborator:
Agency:
Takeda
Agency class:
Industry
Source:
LUNGevity Foundation
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05826756
